<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01636908</url>
  </required_header>
  <id_info>
    <org_study_id>2011/128</org_study_id>
    <nct_id>NCT01636908</nct_id>
  </id_info>
  <brief_title>Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.</brief_title>
  <acronym>ICK</acronym>
  <official_title>Pilot Study on the Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine intratumoral concentration of kinase inhibitors
      upon 2 weeks of treatment in tumor tissue of patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be cohort-wise treated with clinically available kinase inhibitors for 2 weeks
      prior to standard palliative treatment. Five patients will be included in each of eight drug
      cohorts. Biopsies will be performed to determine intratumoral drug concentrations and to
      compare tissue (phospho)proteomic and kinase activity profiles before and during therapy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2011</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>concentrations of intratumoral kinase inhibitors upon 2 weeks of treatment</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>kinase inhibitor concentrations in plasma, serum and PBMC's upon 2 weeks of treatment</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intra-dermal kinase inhibitor concentrations upon 2 weeks of treatment</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine per patient whether 2 weeks of treatment with kinase inhibitors induces significant change of phosphoproteomic profiles in tumor tissue</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine per patient whether 2 weeks of treatment with kinase inhibitors induces significant change of kinase activity in tumor tissue</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Cancer</condition>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Kinase inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are cohort-wise treated with a registered (tyrosine) kinase inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>50 mg once daily, oral use, 14 days</description>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>400 mg, twice daily, oral use, 14 days</description>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>150 mg once daily, oral use, 14 days</description>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>10 mg once daily, oral use, 14 days</description>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <description>1250 mg once daily, oral use, 14 days</description>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>100 mg once daily, oral use, 14 days</description>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>800 mg once daily, oral use, 14 days</description>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib</intervention_name>
    <description>960 mg twice daily, oral use, 15-21 days</description>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>tumor biopsy</intervention_name>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>skin biopsy (optional)</intervention_name>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced solid malignancy

          -  minimum age 18 years

          -  indication for palliative treatment

          -  measurable disease with at least one lesion accessable for biopsy

        Exclusion Criteria:

          -  Cardiovascular conditions including congestive heartfailure NYHA class &gt;2

          -  recent myocardial infarction or uncontrolled coronary artery disease

          -  cardiac arrhythmias requiring anti-arrhythmic therapy

          -  uncontrolled hypertension

          -  uncontrolled infections

          -  serious non-healing wound, ulcer or bone fracture

          -  pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H.M.W. Verheul, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU Medical Center Amsterdam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VUMedical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2012</study_first_submitted>
  <study_first_submitted_qc>July 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2012</study_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>H.M.W. Verheul</investigator_full_name>
    <investigator_title>Head Department Medical Oncology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Vemurafenib</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

